Photo from Jonathan Cohen/LinkedIn
Apr 13, 2024, 14:18
Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society
Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center, shared on LinkedIn:
“I had the opportunity to discuss various topics in hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society (ISCORT).
Some points of discussion:
- Should all HCC patients undergo biopsies?
– This will probably become SOC soon with ADC’s and other biomarker-driven therapies; but not yet. - When should systemic therapies be introduced?
– Adjuvant data is not ripe, but I would strongly consider when loco-regional disease recurs. Survival data will be crucial.
– Neoadjuvant treatment makes sense. Awaiting data.
– Downstaging with ICI before liver transplant – some ongoing single institution studies. Risk of rejection? Loss of systemic protection due to immune-suppression? vs. potential for cure? - How should increased LFT’s be handled in HCC patients receiving ICI?
– Don’t rush to label as irAE. - What’s going on in the clinical research arena for HCC?
– ADC’s
– Immune-cell engagers
– Novel combinations
– Personalized neoantigen vaccine.”
View additional information.
Source: Jonathan Cohen/LinkedIn
ADCs
Antibody drug conjugates
cancer
clinical research
Hadassah Medical Center
HCC
hepatocellular carcinoma
immune checkpoint inhibition
immune related adverse events
irAE
ISCORT
Jonathan Cohen
LFTs
liver function tests
neoadjuvant treatment
OncoDaily
Oncology
Sharett Institute of Oncology
sraeli oncology society
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14